SHFL: A Potential Drug Target and Biomarker for Cancer (G55337)

Target Name: SHFL

NCBI ID: G55337

SHFL

SHFL: A Potential Drug Target and Biomarker for Cancer

SHFL (C19orf66) is a protein that is expressed in various tissues throughout the body. It is a key regulator of cell adhesion and has been implicated in a number of diseases, including cancer.

Recent studies have suggested that SHFL may be a drug target or biomarker for a number of diseases, including cancer. This is because SHFL has been shown to play a role in the regulation of cell adhesion, which is a critical process that allows cells to stick together and form tissues.

One of the ways that SHFL is thought to work is by regulating the activity of integrins, which are proteins that help cells stick together. Integrins are involved in many different processes in the body, including tissue formation, wound healing, and immune response.

Research has suggested that SHFL may be a drug target because it is involved in the regulation of cell adhesion, which is often disrupted in many diseases, including cancer. By targeting SHFL, researchers may be able to develop new treatments for these diseases.

In addition to its role in cell adhesion, SHFL has also been shown to play a role in the regulation of cell signaling pathways. This is important because many diseases are caused by the disruption of normal cell signaling pathways.

For example, SHFL has been shown to regulate the signaling pathway known as the TGF-β pathway. This pathway is involved in the regulation of cell growth, differentiation, and inflammation. Disruptions in the TGF-β pathway have been implicated in a number of diseases, including cancer.

Research has also suggested that SHFL may be a biomarker for some diseases, such as cancer. This is because SHFL is often expressed at higher levels in cancer cells than in healthy cells. By detecting SHFL levels in cancer cells, researchers may be able to develop new diagnostic tests for these diseases.

Overall, SHFL is a protein that is involved in a number of important processes in the body. Its role in cell adhesion and signaling pathways makes it a potential drug target and biomarker for a number of diseases. Further research is needed to fully understand the role of SHFL in these processes and to develop new treatments for the diseases it is involved in.

Protein Name: Shiftless Antiviral Inhibitor Of Ribosomal Frameshifting

Functions: Inhibits programmed -1 ribosomal frameshifting (-1PRF) of a variety of mRNAs from viruses, such as HIV1, and cellular genes, such as PEG10. Interacts with the -1PRF signal of target mRNA and translating ribosomes and causes premature translation termination at the frameshifting site (PubMed:30682371). Regulates HIV1 GAG-POL expression by inhibiting -1PRF (PubMed:30682371). Exhibits antiviral activity against dengue virus (DENV) and can inhibit the replication of all DENV serotypes. May block the protein translation of DENV RNA via its association with cellular mRNA-binding proteins and viral RNA. Interrupts also Zika virus replication by promoting viral NS3 degradation via a lysosome-dependent pathway (PubMed:32150556). Can also limit the replication of hepatitis C virus (HCV) by restricting formation of viral replication organelle, West Nile virus (WNV), Chikungunya virus (CHIKV), herpes simplex virus type 1 (HHV-1), herpes virus type 8 (HHV-8) and human adenovirus (PubMed:26735137, PubMed:27974568, PubMed:30944177, PubMed:32294532). Binds nucleic acids with a higher affinity for ssRNA and ssDNA than for dsDNA (PubMed:27974568)

The "SHFL Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SHFL comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets